CB1 receptor blockade and its impact on cardiometabolic risk factors: Overview of the RIO programme with rimonabant

Journal of Neuroendocrinology

Volumn 20, Issue SUPPL. 1, 2008, Pages 139-146

  Scheen, Andre J ^a  

^a CHU SART TILMAN   (Belgium)

Author keywords

Cardiometabolic risk; CB1 receptor; Endocannabinoid system; Obesity; Rimonabant; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; C REACTIVE PROTEIN; CANNABINOID 1 RECEPTOR ANTAGONIST; ENDOCANNABINOID; HIGH DENSITY LIPOPROTEIN; METFORMIN; PLACEBO; RIMONABANT; SR 141716 A; SULFONYLUREA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL OBESITY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY DISORDER; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DIZZINESS; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATTY LIVER; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MENTAL DISEASE; METABOLIC SYNDROME X; MOOD DISORDER; NAUSEA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PLASMA CONCENTRATION-TIME CURVE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SUICIDAL IDEATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ALGORITHMS; ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X; METFORMIN; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RISK FACTORS; TREATMENT OUTCOME;

EID: 42449151676     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2008.01681.x     Document Type: Conference Paper

References (50)

1. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 73-100.
2. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007; 18: 27-37.
3. Cota D. CB1 receptors: Emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 2007; 23: 507-517.
4. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-784.
5. Pacher P, Batkai S, Kunos G. The endocannabioid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462.
6. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L, Festy F, Pasquali R, Roche R, Maj M, Pagotto U, Monteleone P, Di Marzo V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. J.Clin Endocrinol Metab 2006; 91: 3171-3180.
7. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Després JP, Di Marzo V. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obesity 2007; 31: 692-699.
8. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887.
9. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875-880.
10. Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 2003; 63: 1165-1184.
11. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
12. IDF Clinical Guidelines Task force. Global guideline for type 2 diabetes: Recommendations for standard, comprehensive, and minimal care. Diabet Med 2006; 23: 579-593.
13. Mikhailidis DP, Press M. The importance of treating multiple cardiometabolic risk factors in patients with type 2 diabetes. Expert Opin Pharmacother 2007; 8: 3009-3020.
14. Scheen AJ, Van Gaal LF, Després J-P, Pi-Sunyer X, Golay A, Hanotin C. Le rimonabant améliore le profil de risque cardio-métabolique chez le sujet obèse ou en surpoids: synthèse des études "RIO". Rev Med Suisse 2006; 2: 1916-1923.
15. Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006; 4: 4.
16. Henness S, Robinson DM, Lyseng-Williamson KA. Rimonabant. Drugs 2006; 66: 2109-2119. discussion 2120-1.
17. Xie S, Furjanic MA, Ferrara JJ, McAndrew NR, Ardino EL, Ngondara A, Bernstein Y, Thomas KJ, Kim E, Walker JM, Nagar S, Ward SJ, Raffa RB. The endocannabinoid system and rimonabant: A new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism -or inverse agonism -as potential obesity treatment and other therapeutic use. J.Clin Pharm Ther 2007; 32: 209-231.
18. http://www.emea.europa.eu/humandocs/Humans/EPAR/acomplia/acomplia.htm (accessed 16 January 2008).
19. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S and RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
20. 1 blockade with rimonabant on cardiometabolic risk factors: 2-year results from the RIO-Europe Study. Eur Heart J 2008; 29 (in press).
21. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J and RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: A randomized controlled trial. JAMA 2006; 295: 761-775.
22. Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group. Effects on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134.
23. Cote M, Mauriege P, Bergeron J, Almeras N, Tremblay A, Lemieux I, Després JP. Adiponectinemia in visceral obesity: Impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J.Clin Endocrinol Metab 2005; 90: 1434-1439.
24. Guerre-Millo M. Adiponectin: An update. Diab Metab 2008; 34: 12-18.
25. Després JP, Van Gaal L, Scheen A, Pi-Sunyer X. Rimonabant improves cardiometabolic risk factors in overweight/obese patients irrespective of treatment with statins: Pooled data from the RIO program (Abstract). Atherosclerosis 2006; 7 (Suppl. 3): 329.
26. Ruilope LM, Després JP, Scheen A, Pi-Sunyer X, Mancia G, Zanchetti A, Van Gaal L. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: Analysis of pooled Rimonabant In Obesity (RIO) study results. J.Hypertens 2008; 26: 357-367.
27. Pi-Sunyer F-X, Després J-P, Scheen A, Van Gaal L. Improvement of metabolic effects with rimonabant beyond the effect attributable to weight loss alone: Pooled one year data from the RIO (Rimonabant In Obesity and Related Metabolic Disorders) program (Abstract). JACC 2006; 47 (Suppl. A): 362-A.
28. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF for the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 2006; 368: 1660-1672.
29. Després JP, Van Gaal L, Golay A, Rissanen A. Rimonabant improves oral glucose tolerance in non-diabetic overweight/obese patients with/ without comorbidities (Abstract). Diabetes 2006; 55 (Suppl. 1): A80-A81.
30. Scheen AJ. The endocannabinoid system, a promising target for the management of type 2 diabetes. Curr Protein Pept Sci 2008; in press.
31. Scheen A, Van Gaal L. The CB1 blocker rimonabant reduces liver enzyme levels in overweight/obese people with type 2 diabetes: The RIO Diabetes study (Abstract). Diabetic Med 2006; 23 (Suppl. 4): 251-252.
32. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S, Harvey-White J, Mackie K, Offertáler L, Wang L, Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J.Clin Invest 2005; 115: 1298-1305.
33. Luyckx FH, Scheen AJ, Lefèbvre PJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 2000; 26: 98-106.
34. Rosenstock J, Iranmanesh A, Hollander PA. Improved glycemic control with weight loss plus beneficial effects on atherogenic dyslipidemia with rimonabant in drug-naïve type 2 diabetes: The SERENADE trial (Abstract). Diabetes 2007; 56 (Suppl. 1): A49-A50.
35. Lafontan M, Piazza PV, Girard J. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. Diabetes Metab 2007; 33: 85-95.
36. Scheen AJ. Cannabinoid-1 receptor antagonists in type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007; 21: 535-553.
37. Anderson JW, Kendall CWC, Jenkins DJA. Importance of weight management in type 2 diabetes: Review with meta-analysis of clinical studies. J.Am Coll Nutr 2003; 22: 331-339.
38. Joffe D, Yanagisawa RT. Metabolic syndrome and type 2 diabetes: Can we stop the weight gain with diabetes. Med Clin North Am 2007; 91: 1107-1123.
39. Van Gaal LF, Pi-Sunyer X, Després JP, Mc Carthy C, Scheen AJ. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: Pooled 1-year data from the RIO program. Diabetes Care 2008; 31 (Suppl. 2): S229-S240.
40. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Lancet 2007; 370: 1706-1713.
41. Food and Drug Administration. http://www.fda.gov/ohrms/dockets/ac/07/ briefing/2007-4306b1-00-index.htm.
42. Serra G, Fratta W. A possible role for the endocannabinoid system in the neurobiology of depression. Clin Pract Epidemiol Mental Health 2007; 3: 25.
43. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohórquez SM, Stoch A, Stevens C, Fong TM, De Lepeleire I, Cilissen C, Cote J, Rosko K, Gendrano IN III, Nguyen AM, Gumbiner B, Rothenberg P, de Hoon J, Bormans G, DepréM, Eng WS, Ravussin E, Klein S, Blundell J, Herman GA, Burns HD, Hargreaves RJ, Wagner J, Gottesdiener K, Amatruda JM, Heymsfield SB. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 2008; 7: 68-78.
44. Gadde KM, Allison DB. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation 2006; 114: 974-984.
45. Gelfand EV, Cannon CP. Rimonabant: A cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J.Am Coll Cardiol 2006; 47: 1919-1926.
46. Bifulco M, Grimaldi C, Gazzerro P, Pisanti S, Santoro A. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Mol Pharmacol 2007; 71: 1445-1456.
47. Padwal RS, Majumdar SR. Drug treatments for obesity: Orlistat, sibutramine, and rimonabant. Lancet 2007; 369: 71-77.
48. Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. BMJ 2007; 335: 1194-1199.
49. Bays H, Blonde L, Rosenson R. Adiposopathy: How do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients? Expert Rev Cardiovasc Ther 2006; 4: 871-895.
50. Acomplia European Public Assessment Report. Summary of product characteristics. http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/ H-666-PI-en.pdf. (accessed 21 November 2007).